Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment - PubMed (original) (raw)
Review
Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment
Stephen Y W Shiu. J Pineal Res. 2007 Aug.
Abstract
Prostate cancer is a public health problem of the elderly men. It has been estimated that one in six men will develop prostate cancer in his lifetime in the USA. There is thus a huge clinical demand for effective therapies for the prevention and treatment of the disease. Here, the scientific evidence supporting the effectiveness of melatonin in inhibiting the development and progression of prostate cancer is reviewed. The rational use of melatonin in prostate cancer prevention, stabilization of clinically localized favourable-risk prostate cancer and palliative treatment of advanced or metastatic tumour is discussed within the context of the molecular pathogenesis of the disease.
Comment in
- Melatonin as an adjuvant to therapeutic prostate cancer vaccines.
Connor TP. Connor TP. J Pineal Res. 2008 Sep;45(2):224. doi: 10.1111/j.1600-079X.2008.00563.x. Epub 2008 Jan 21. J Pineal Res. 2008. PMID: 18221313 No abstract available.
Similar articles
- Review of recent evidence in support of a role for statins in the prevention of prostate cancer.
Hamilton RJ, Freedland SJ. Hamilton RJ, et al. Curr Opin Urol. 2008 May;18(3):333-9. doi: 10.1097/MOU.0b013e3282f9b3cc. Curr Opin Urol. 2008. PMID: 18382245 Review. - Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiation-induced apoptosis in prostate cancer cells in vitro.
Sainz RM, Reiter RJ, Tan DX, Roldan F, Natarajan M, Quiros I, Hevia D, Rodriguez C, Mayo JC. Sainz RM, et al. J Pineal Res. 2008 Oct;45(3):258-70. doi: 10.1111/j.1600-079X.2008.00585.x. Epub 2008 Apr 2. J Pineal Res. 2008. PMID: 18384530 - Zinc and prostate cancer: a critical scientific, medical, and public interest issue (United States).
Costello LC, Franklin RB, Feng P, Tan M, Bagasra O. Costello LC, et al. Cancer Causes Control. 2005 Oct;16(8):901-15. doi: 10.1007/s10552-005-2367-y. Cancer Causes Control. 2005. PMID: 16132800 Review. - Pharmacological approaches to reducing the risk of prostate cancer.
Rittmaster RS, Fleshner NE, Thompson IM. Rittmaster RS, et al. Eur Urol. 2009 May;55(5):1064-73. doi: 10.1016/j.eururo.2009.01.037. Epub 2009 Feb 5. Eur Urol. 2009. PMID: 19200641 Review.
Cited by
- Melatonin and Docosahexaenoic Acid Decrease Proliferation of PNT1A Prostate Benign Cells via Modulation of Mitochondrial Bioenergetics and ROS Production.
Tamarindo GH, Ribeiro DL, Gobbo MG, Guerra LHA, Rahal P, Taboga SR, Gadelha FR, Góes RM. Tamarindo GH, et al. Oxid Med Cell Longev. 2019 Jan 9;2019:5080798. doi: 10.1155/2019/5080798. eCollection 2019. Oxid Med Cell Longev. 2019. PMID: 30728886 Free PMC article. - Melatonin Can Strengthen the Effect of Retinoic Acid in HL-60 Cells.
Krestinina O, Fadeev R, Lomovsky A, Baburina Y, Kobyakova M, Akatov V. Krestinina O, et al. Int J Mol Sci. 2018 Sep 21;19(10):2873. doi: 10.3390/ijms19102873. Int J Mol Sci. 2018. PMID: 30248940 Free PMC article. - Melatonin in Edible and Non-Edible Plants.
Koca Çalişkan U, Aka C, Bor E. Koca Çalişkan U, et al. Turk J Pharm Sci. 2017 Apr;14(1):75-83. doi: 10.4274/tjps.33043. Epub 2017 Apr 15. Turk J Pharm Sci. 2017. PMID: 32454597 Free PMC article. Review. - Melatonin Synergizes the Chemotherapeutic Effect of Cisplatin in Ovarian Cancer Cells Independently of MT1 Melatonin Receptors.
Zemła A, Grzegorek I, Dzięgiel P, Jabłońska K. Zemła A, et al. In Vivo. 2017 Sep-Oct;31(5):801-809. doi: 10.21873/invivo.11133. In Vivo. 2017. PMID: 28882945 Free PMC article. - Expression and putative functions of melatonin receptors in malignant cells and tissues.
Ekmekcioglu C. Ekmekcioglu C. Wien Med Wochenschr. 2014 Nov;164(21-22):472-8. doi: 10.1007/s10354-014-0289-6. Epub 2014 Jul 15. Wien Med Wochenschr. 2014. PMID: 25023005 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical